Last reviewed · How we verify
NCT05619055
The Intestinal Dysbacteriosis in the Pathogenesis of Necrotizing Enterocolitis
trial testing Routine treatment in Necrotizing Enterocolitis of Newborn in 30 participants. Status unknown.
31 March 2025
Quick facts
| Lead sponsor | Zuohui Zhao |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 5 November 2022 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Routine treatment — full drug profile →
Conditions studied
- Necrotizing Enterocolitis of Newborn — all drugs for Necrotizing Enterocolitis of Newborn →
Sponsor
Zuohui Zhao
Who can join
Adults 5 Days to 2 Months, any sex, with Necrotizing Enterocolitis of Newborn. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study Description The goal of this observational study is to detect intestinal flora and the metabolic products in premature infants diagnosed as necrotizing enterocolitis. The main questions it aims to answer are: * 1\. Whether there is intestinal flora in the stool of premature infants. * 2\. Are there dysregulated intestinal flora and their metabolic products in premature infants diagnosed as necrotizing enterocolitis. * 3\. The detailed role and underlying mechanism of the intestinal dysbacteriosis and the metabolic products in premature infants diagnosed as necrotizing enterocolitis. Participants, premature infants diagnosed as necrotizing enterocolitis (NEC group), will be asked to collect stool (usually 2 times) for intestinal flora analysis. If there is a comparison group: Researchers will compare premature infants without necrotizing enterocolitis (control group) to see if their intestinal flora and the metabolic products also changed as their NEC counterparts.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05619055
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Routine treatment
Trials testing the same drug.
- NCT05578443 — Efficacy, Safety and Response Predictors of Astragalus Membranaceus on the Improvement of Cognitive Function in Mild-to- · Phase 2 · unknown
- NCT05647473 — Efficacy, Safety and Response Predictors of Adjuvant Astragalus for Cognition in Orthostatic Hypotension · Phase 2 · unknown
- NCT06174181 — Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degenerat · NA · completed
- NCT06386614 — Effect of Frontal Transcranial Direct Current Stimulation on BDNF in Stroke Patients With Cognitive Impairment · NA · recruiting
- NCT06199375 — Effect of Modified Mirror Therapy in Patients With Upper Limb Hemiparesis After Stroke · NA · terminated
Other recruiting trials for Necrotizing Enterocolitis of Newborn
Currently open trials in the same condition.
- NCT07152106 — Amniotic Fluid & the Preterm Gut · recruiting
- NCT06632314 — Impact of Enteral Feeding on Splanchnic Oxygenation During Packed Red Blood Cell Transfusion in Preterm Infants · NA · active not recruiting
- NCT03997266 — NICU Antibiotics and Outcomes Trial · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05619055 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zuohui Zhao
- Last refreshed: 16 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05619055.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing